Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
49.28
+0.59 (+1.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Via
InvestorPlace
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the...
Via
Benzinga
Why Is Auddia (AUUD) Stock Up 192% Today?
April 08, 2024
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private
April 08, 2024
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.
Via
InvestorPlace
Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts
April 08, 2024
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
How Is The Market Feeling About Sanofi?
March 27, 2024
Via
Benzinga
(SNY) - Analyzing Sanofi's Short Interest
March 08, 2024
Via
Benzinga
Why the dividend investor may take a look at NASDAQ:SNY.
February 14, 2024
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics.
Via
Chartmill
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
April 04, 2024
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
March 27, 2024
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca...
Via
Benzinga
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'
March 26, 2024
Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand.
Via
Benzinga
To the Moon and Beyond: 7 Stocks With Cosmic Potential
March 14, 2024
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.
Via
InvestorPlace
NASDAQ:SNY is an undervalued gem with solid fundamentals.
February 14, 2024
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings
March 13, 2024
With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities.
Via
InvestorPlace
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.
Via
Benzinga
3 Cash Cow Dividend Stocks for Outsized Income & Upside
February 27, 2024
With uncertainty again weighing on the market, investors can take shelter under these cash cow dividend stocks.
Via
InvestorPlace
6 reasons to buy Teva Pharmaceuticals stock sooner than later
February 26, 2024
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.
Via
InvestorPlace
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
February 20, 2024
The FDA put studies in eczema and asthma treatment on clinical hold.
Via
Investor's Business Daily
Exposures
Product Safety
Cruising For A Bruising
February 18, 2024
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft...
Via
Talk Markets
Topics
Economy
Exposures
Economy
Interest Rates
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
February 16, 2024
Don't count these companies out too soon.
Via
The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Via
InvestorPlace
What's Going On Eli Lilly Stock Thursday?
February 08, 2024
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews.
Via
Benzinga
Novo Nordisk To Up Production Capacity As Parent Buys Catalent
February 05, 2024
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash.
Via
Investor's Business Daily
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
February 05, 2024
Click here to learn more about CytoReason and how to invest through OurCrowd.
Via
Benzinga
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Via
Talk Markets
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
February 02, 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Via
Benzinga
Sanofi (SNY) Q4 2023 Earnings Call Transcript
February 01, 2024
SNY earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.